Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 14/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 7/20 | 0.45 |
| ▸ | PTPRC | P08575 | 2/20 | 0.39 |
| ▸ | CMA1 | P23946 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4898651 | 0.91 | PTPN1 (0.42) | PTPN1PTPN2PTPRC | |
| SCHEMBL4895481 | 0.88 | PTPN1 (0.45) | PTPN1PTPN2PTPRCHDAC1HDAC11 | |
| SCHEMBL4898664 | 0.88 | PTPN1 (0.45) | PTPN1PTPN2PTPRCHDAC1HDAC11 | |
| SCHEMBL4901693 | 0.87 | PTPN1 (0.44) | PTPN1PTPN2PTPRCPTGER4 | |
| SCHEMBL4898619 | 0.87 | PTPN1 (0.43) | PTPN1PTPN2PTPRCHDAC1HDAC11 | |
| SCHEMBL4901303 | 0.86 | PTPN1 (0.46) | PTPN1PTPN2PTPRCPTGER4 | |
| SCHEMBL4891956 | 0.84 | PTPN1 (0.42) | PTPN1PTPN2PTPRC | |
| SCHEMBL4889729 | 0.84 | PTPN1 (0.42) | PTPN1PTPN2PTPRCHDAC1HDAC11 | |
| SCHEMBL4901271 | 0.82 | PTPN1 (0.41) | PTPN1PTPN2PTPRCHDAC1HDAC11 | |
| SCHEMBL4898665 | 0.81 | PTPN1 (0.39) | PTPN1PTPN2PTPRCPTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070867-A1 | 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases | METABASIS THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | US | claimed |
| US-20080070867-A1 | 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases | METABASIS THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070867-A1 | 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases | PPM1B, PPM1D, PTPRS | PTPN1 13/4885PTPN2 27/4885PTPRC 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.